4-Hydroxynonenal dependent alteration of TRPV1-mediated coronary microvascular signaling

Daniel J DelloStritto1, Pritam Sinharoy2, Patrick J Connell1

  • 1Department of Integrative Medical Sciences, Northeast Ohio Medical University, 4209 St. Rt. 44, Rootstown, OH 44272, USA.

Insights

Oxidative stress in diabetes disrupts coronary blood flow by modifying TRPV1 channels. A specific cysteine mutation (C621) rescues TRPV1 function, suggesting a target for treating diabetic microvascular dysfunction.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Biology
  • Diabetic Complications

Background:

  • Coronary blood flow (CBF) regulation via TRPV1 channels is impaired in diabetes.
  • Endothelial TRPV1 function is lost in a diabetic oxidative environment, linked to 4-Hydroxynonenal (4-HNE) byproduct.
  • 4-HNE causes post-translational modifications (PTMs) on proteins, potentially affecting TRPV1.

Purpose of the Study:

  • To investigate if 4-HNE-mediated PTM of TRPV1 causes its dysfunction in diabetes.
  • To identify specific sites of 4-HNE modification on TRPV1.
  • To determine if mutating these sites can restore TRPV1 function.

Main Methods:

  • In vivo studies: 4-HNE infusion in mice to measure CBF.
  • In vitro studies: Isolated mouse coronary arterioles to assess vasorelaxation.
  • Electrophysiology (patch-clamp) and calcium imaging to measure TRPV1 currents and Ca2+ entry.
  • Molecular modeling to predict 4-HNE modification sites.
  • Site-directed mutagenesis of TRPV1 (C621G mutant).
  • Biochemical assays (His tag pull-down) to confirm 4-HNE binding to TRPV1.

Main Results:

  • 4-HNE infusion reduced TRPV1-dependent CBF in wild-type mice.
  • 4-HNE suppressed TRPV1-mediated vasorelaxation in isolated arterioles.
  • 4-HNE inhibited TRPV1 currents and Ca2+ influx.
  • Mutation of pore Cysteine 621 (C621G) completely restored capsaicin-induced TRPV1 activation.
  • 4-HNE showed increased binding to wild-type TRPV1, which was reduced in the C621G mutant.

Conclusions:

  • 4-HNE directly modifies TRPV1, leading to impaired channel function at both in vivo and in vitro levels.
  • Modification at Cysteine 621 is critical for 4-HNE-induced TRPV1 dysfunction.
  • Targeting 4-HNE modification of TRPV1 may offer a therapeutic strategy for diabetic microvascular complications.